CIMZIA ® is the only Fc-free, PEGylated anti-TNF (Tumor Necrosis Factor). CIMZIA ® has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha.

In the initial EXXELERATE trial comparing the efficacy of CIMZIA and adalimumab, the primary endpoints of superiority were not met. In the post hoc analysis, efficacy outcomes in CIMZIA and ...

Cimzia will compete against three existing anti-TNF drugs -- Amgen's Enbrel, Johnson & Johnson's Remicade and Abbott Laboratories Inc.'s Humira -- that can cost $10,000 to $30,000 per patient a year.

Belgian drugmaker UCB <UCBBt.BR> is still hoping to launch its Crohn's disease drug Cimzia in the United States in the first half of 2007 and does not think further clinical trials will be needed ...

Initiate treatment for latent TB prior to CIMZIA use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis.